Skip to content

Vicore Pharma publishes the Annual Report for 2022

Stockholm, April 5, 2023 –Vicore Pharma Holding AB (publ) (“Vicore” or “company”) unlocking the potential of a new class of drugs – angiotensin II type 2-receptor agonists (ATRAGs), today announced the publication of the Annual Report for the financial year 2022.

The Annual Report for the financial year 2022 is available on the company’s website:

For further information, please contact:
Hans Jeppsson, CFO, tel: +46 70 553 14 65,  

About Vicore Pharma Holding AB (publ)
Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life changing treatments in diseases where the AT2 (angiotensin II type 2) receptor has a central role in stopping and reversing disease pathology. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG). Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. With our unique expertise in the ATRAG biology we fuel our pipeline with several new assets with long patent life for a variety of diseases, some of which could be partnered while others can be taken to the market by Vicore itself.

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see

This information is information that Vicore Pharma Holding is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-05 08:00 CEST.

Vicore Annual Report 2022


Source: Vicore Pharma